BJH - volume 9, issue Multiple Myeloma Special Edition, december 2018
M. Delforge MD, PhD
For the majority of multiple myeloma (MM) patients, their disease will behave as a chronic disorder with episodes of remission followed by disease progression. Whereas the treatment approach in frontline is rather uniform, treatment at relapse has become more heterogeneous, as therapeutic choices at this stage are driven by many factors including disease characteristics and patient status, but also the previous treatment(s), their therapeutic effect and toxicities, and drug availability. With each treatment course patients also tend to become more vulnerable to hematological and non-hematological toxicities. Therefore, particularly at later relapses where there is no standard of care, the benefits and potential risks of therapeutic decisions should be carefully balanced in each individual patient, to minimize excess toxicities. In this review article, an overview is provided of the currently available treatment options for patients with relapsed or refractory MM.
Read moreBJH - volume 9, issue Multiple Myeloma Special Edition, december 2018
A. Van De Velde MD, PhD, M. Timmers , P. Vlummens MD, S. Anguille MD, PhD
New therapeutic antibodies and T cells redirected to specific antigen targets with engineered chimeric antigen receptors (CARs) are emerging as powerful therapies in haematologic malignancies and multiple myeloma (MM). Various designs, manufacturing processes, and study populations, among other variables, have been tested and reported in clinical trials in MM. Here, we review and compare ongoing trials and the results of the reported clinical trials. We also discuss the outlook for CAR-T cell therapies, including managing toxicities and expanding the availability of personalized cell therapy as a promising approach to all haematologic malignancies.
Read moreBJH - volume 9, issue Multiple Myeloma Special Edition, december 2018
M. Vercruyssen MD, N. Meuleman MD, PhD
Patients with multiple myeloma (MM) not only require treatments directed at their disease activity, but also need a wide range of supportive measures. In this review article supportive measures with respect to anaemia, infections, thromboembolic risk, bone disease, peripheral neuropathy and pain are discussed.
Read more
Top
